Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mesoblast ADR Representing 10 Ord Shs MESO

Healthcare Biotechnology
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for... see more

Recent & Breaking News (NDAQ:MESO)

Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease

GlobeNewswire February 10, 2021

Mesoblast Corporate Update

GlobeNewswire February 10, 2021

Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020

GlobeNewswire January 28, 2021

Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference

GlobeNewswire January 11, 2021

Mesoblast Webcast - Update on COVID-19 ARDS Trial

GlobeNewswire December 17, 2020

Mesoblast Update on COVID-19 ARDS Trial

GlobeNewswire December 17, 2020

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure

GlobeNewswire December 14, 2020

Mesoblast Corporate Update

GlobeNewswire December 14, 2020

MESO ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 7, 2020 in the Class Action Filed on Behalf of Mesoblast Limited Limited Shareholders

Newsfile December 7, 2020

MESO Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Mesoblast Limited Investors of Class Action and Deadline: December 7, 2020

ACCESSWIRE IA December 7, 2020

FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mesoblast Limited and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm

ACCESSWIRE IA December 7, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Mesoblast Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 7, 2020 - MESO

Newsfile December 7, 2020

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mesoblast Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile December 7, 2020

MESO Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Mesoblast Limited Investors of Class Action and Lead Plaintiff Deadline: December 7, 2020

GlobeNewswire December 7, 2020

MESO Final Deadline Today: Rosen, Leading Trial Attorneys, Reminds Mesoblast Limited Investors of Important December 7 Deadline in Securities Class Action - MESO

Newsfile December 7, 2020

Remestemcel-L Reduces Inflammatory Biomarkers Predictive of High Mortality in Acute Graft Versus Host Disease

GlobeNewswire December 7, 2020

FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mesoblast Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA December 7, 2020

MESO FINAL MONDAY DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mesoblast Limited Investors Seek Counsel Before Important December 7 Deadline in Securities Class Action - MESO

ACCESSWIRE IA December 6, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mesoblast Limited of Class Action Law Suit and Upcoming Deadline - MESO

PR Newswire December 5, 2020

MESO FINAL DEADLINE MONDAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Mesoblast Limited Investors of Important December 7 Deadline in Securities Class Action - MESO

Business Wire December 5, 2020